Effective Drug Regulation - A Multicountry Study and Annex 1: Guide for Data Collection to Assess Drug Regulatory Performance
(2002; 187 pages) Ver el documento en el formato PDF
Índice de contenido
Ver el documentoACRONYMS
Ver el documentoPREFACE
Ver el documentoACKNOWLEDGEMENTS
Ver el documentoEXECUTIVE SUMMARY
Abrir esta carpeta y ver su contenido1. DRUG REGULATION: OBJECTIVES AND ISSUES
Abrir esta carpeta y ver su contenido2. MULTICOUNTRY STUDY ON EFFECTIVE DRUG REGULATION
Abrir esta carpeta y ver su contenido3. PROFILE OF THE COUNTRIES
Abrir esta carpeta y ver su contenido4. REGULATORY FRAMEWORK
Abrir esta carpeta y ver su contenido5. REGULATORY CAPACITY
Abrir esta carpeta y ver su contenido6. LICENSING OF MANUFACTURING, DISTRIBUTION AND RETAIL SALE
Abrir esta carpeta y ver su contenido7. INSPECTION AND SURVEILLANCE
Cerrar esta carpeta8. PRODUCT ASSESSMENT AND REGISTRATION
Ver el documento8.1 POWER AND PROCESS
Ver el documento8.2 HUMAN RESOURCES
Ver el documento8.3 PAYING FOR REGISTRATION
Ver el documento8.4 PERFORMANCE
Ver el documento8.5 ADVERSE DRUG REACTION MONITORING
Ver el documento8.6 CLINICAL TRIALS
Abrir esta carpeta y ver su contenido9. CONTROL OF DRUG PROMOTION AND ADVERTISING
Abrir esta carpeta y ver su contenido10. DRUG QUALITY CONTROL LABORATORY
Abrir esta carpeta y ver su contenido11. ASSESSING REGULATORY PERFORMANCE
Abrir esta carpeta y ver su contenido12. CONCLUSIONS AND RECOMMENDATIONS FOR EFFECTIVE DRUG REGULATION
Abrir esta carpeta y ver su contenidoANNEX 1: GUIDE FOR DATA COLLECTION TO ASSESS DRUG REGULATORY PERFORMANCE
 

8. PRODUCT ASSESSMENT AND REGISTRATION

Product assessment and registration (also known as marketing authorization and product licensing) are carried out by drug regulatory authorities to ensure that a pharmaceutical product has been adequately tested and evaluated for safety, efficacy and quality and that the product information provided by the manufacturer is accurate. They involve evaluating technical and administrative data submitted about a drug product, deciding whether to approve or reject the product, issuing a marketing authorization (certificate) and conducting ADR monitoring. The overall process requires a legal foundation, an adequate number of qualified staff, sustainable resources, a data retrieval system and a system to ensure freedom from conflicts of interest, accountability and transparency. GMP inspection and QC services are also necessary to ensure that GMP requirements are adhered to and to carry out quality testing. This chapter describes the drug assessment and registration situation in the 10 countries.

Ir a la sección anterior Ir a la siguiente sección
 

Última actualización: le 3 mayo 2013